174180-42-8

Basic information

• Product Name: 1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester
• Synonyms: 1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester;TERT-BUTYL 3-(BROMOMETHYL)-1H-INDAZOLE-1-CARBOXYLATE;3-BroMoMethyl-indazole-1-carboxylic acid tert-butyl ester;1-Boc-3-(broMoMethyl)-1H-indazole;3-(Bromomethyl)-1H-indazole,N1-BOCprotected
• CAS NO: 174180-42-8
• Molecular Formula: C₁₃H₁₅BrN₂O₂
• Molecular Weight: 311.1744
• Mol File: 174180-42-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 400.326 °C at 760 mmHg
• Flash Point: 195.91 °C
• Appearance: /
• Density: 1.418 g/cm³
• CAS DataBase Reference: 1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester(174180-42-8)
• EPA Substance Registry System: 1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester(174180-42-8)

Safety Data

• Hazardous Substances Data: 174180-42-8(Hazardous Substances Data)

Usage

General Description

1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester, typically referred to as 1H-Indazole-1-carboxylic acid 3-bromomethyl ester, is a chemical compound that falls under the category of Indazoles. Indazoles are organic compounds containing an indazole, which is a monocyclic heterocycle made up of two benzene rings fused to a pyrazole ring. The structure of this particular indazole derivative is characterized by a 3-(bromomethyl) group attached to the indazole ring and an ester functional group attached to the 1-position on the ring. The precise properties and potential uses of this compound are highly dependent on its specific molecular context; detailed research and experimentation would be needed to fully define these characteristics.

Upstream product

• 174180-72-4 2-methyl-2-propanyl 3-methyl-1H-indazole-1-carboxylate 
• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 64132-13-4 3-(hydroxymethyl)-1H-indazole 
• 882188-87-6 tert-butyl 3-(hydroxymethyl)-1H-indazole-1-carboxylate 
• 43120-28-1 methyl 1H-indazole-3-carboxylate 
• 3176-62-3 3-methyl-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 445-27-2 2'-Fluoroacetophenone 

Downstream Products

• 871365-74-1 N-(2,2-diethoxyethyl)-N-phenyl 2-(1-tert-butyloxycarbonyl-1H-indazol-3-ylmethyl)malonamide 
• 174181-13-6 2-[3-(1-tert-butoxycarbonyl-1H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-phenyl-acetamide 
• 179083-74-0 tert-butyl 3-(3-((2,2-diethoxyethyl)(phenyl)amino)-2-(2-(isopropyl(4-methoxyphenyl)amino)-2-oxoethylcarbamoyl)-3-oxopropyl)-1H-indazole-1-carboxylate 

Relevant articles and documents

Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities

A series of indazolyl-substituted piperidin-4-yl-aminopyrimidines (IPAPYs) were designed from two potent HIV-1 NNRTIs piperidin-4-yl-aminopyrimidine 3c and diaryl ether 4 as the lead compounds by molecular hybridization strategy. The target molecules 5a-q

EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed herein are compounds and methods of use thereof for the modulation of EphA4 receptor activity. In an aspect, is provided a method of treating or preventing a disease or disorder mediated by EphA4, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein, including certain embodiments, or the structural Formula (I), (l-A), (II), (III), (IV), (IV-1), (V), (Vl-A), (Vl-B), (VII-1), (VII-2), (VIII-1), or (VIII-2), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

HIV reverse transcriptase inhibitors

Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.